Evrenzo 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification0F
Decision 
Information 
1 issued on 
Issued1F
2 / 
affected2F
3  
IB/0006/G 
This was an application for a group of variations. 
02/06/2023 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IB/0004 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
27/02/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/10955
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
/202206 
roxadustat 
PSUSA/10955
Periodic Safety Update EU Single assessment - 
21/07/2022 
30/09/2022 
SmPC 
Refer to Scientific conclusions and grounds recommending 
/202112 
roxadustat 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10955/202112. 
II/0002 
Update of section 4.8 of the SmPC in order to add 
23/06/2022 
30/09/2022 
SmPC and 
Update of section 4.8 of the SmPC in order to add 
dermatitis exfoliative generalised (DEG) to the list of 
Annex II 
dermatitis exfoliative generalised (DEG) to the list of 
adverse drug reactions (ADRs) with frequency 
adverse drug reactions (ADRs) with frequency unknow 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
unknow based on post-marketing data and literature. 
In addition, the MAH took the opportunity to amend 
the Annex IIB in order to reflect the fact that 
restricted prescription applies. 
Furthermore, the MAH took the opportunity to 
implement editorial changes to the SmPC 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
based on post-marketing data and literature. PL was 
updated accordingly.  
For more information, please refer to the Summary of 
Product Characteristics. 
Page 3/3 
 
 
 
 
 
 
 
 
